# ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness

> **NCT07084558** · NA · RECRUITING · sponsor: **Austrian Breast & Colorectal Cancer Study Group** · enrollment: 350 (estimated)

## Conditions studied

- Early and Locally Advanced Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** blood sample for Signatera (TM) test
- **DIAGNOSTIC_TEST:** biopsy for Ki-67 assessment
- **DIAGNOSTIC_TEST:** FFPE tumor sample for Signatera (TM) test (archived)

## Key facts

- **NCT ID:** NCT07084558
- **Lead sponsor:** Austrian Breast & Colorectal Cancer Study Group
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-13
- **Primary completion:** 2028-06-30
- **Final completion:** 2033-06-30
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2025-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07084558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07084558, "ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07084558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*